

MR. CHARLES HAY (Orcid ID : 0000-0003-3496-7044)

DR. EDWARD RODDY (Orcid ID : 0000-0002-8954-7082)

Article type : Reply to Letter to the Editor

Reply to Dr. Lai regarding Allopurinol Hypersensitivity Syndrome in patients of Asian ancestry

Charles A Hay MA¹, James A Prior PhD^{1, 2}, Christian D Mallen PhD¹, John Belcher PhD³, Ed Roddy PhD¹

Affiliations:

¹ School of Medicine, Keele University, UK

² Department of International Public Health, Liverpool School of Tropical Diseases, UK

³ School of Computing and Mathematics, Keele University, UK

Mr Charles A Hay

School of Medicine,

Keele University,

Staffordshire,

ST5 5BG,

United Kingdom

Email – c.hay@keele.ac.uk

Tel - 01782 734986

Word Count: 168

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/acr.24777](https://doi.org/10.1002/acr.24777)

This article is protected by copyright. All rights reserved

Sir,

We thank Dr Lai for their interest in our study (1). While we did not show a statistically significant link between the use of allopurinol and mortality in people with gout, we agree that Allopurinol Hypersensitivity Syndrome (AHS) is the most serious side-effect of allopurinol, particularly in populations with South East Asian ancestry, leading to the recommendation to screen people of South East Asian descent for the HLA-B*5801 allele prior to starting treatment with allopurinol (2,3).

While AHS can be fatal, its incidence is low. One study reported an incidence of AHS in a large South East Asian sample of 4.68 per 1000 new users of allopurinol and related mortality of 0.39 per 1000 new users (4).

Investigation of the mortality risk from AHS was outside the purview of our study, which aimed to compare all-cause and cardiovascular mortality between allopurinol users and non-users, but we agree AHS is an important consideration for all clinicians managing gout, of which all patients starting allopurinol should be made aware.

Funding

CAH is funded by a NIHR School for Primary Care Research PhD Studentship. CDM is funded by the NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands, the NIHR SPCR, and an NIHR Research Professorship in General Practice (NIHR-RP-2014-04-026). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR (UK). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Conflicts of Interest

The authors declare they have no conflicts of interest

References

1. Hay CA, Prior JA, Belcher J, Mallen CD, Roddy E. Mortality in Patients With Gout Treated With Allopurinol: A Systematic Review and Meta-Analysis. *Arthritis Care & Research*. 2021;73(7):1049–54.

- Accepted Article
2. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. *Arthritis Care Res (Hoboken)*. 2020 Jun;72(6):744–60.
 3. Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British Society for Rheumatology Guideline for the Management of Gout. *Rheumatology*. 2017 Jul 1;56(7):e1–20.
 4. Yang C-Y, Chen C-H, Deng S-T, Huang C-S, Lin Y-J, Chen Y-J, et al. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan. *JAMA Internal Medicine*. 2015 Sep 1;175(9):1550–7.